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Abstract Morphea, also known as localized scleroderma,
encompasses a group of idiopathic sclerotic skin diseases. The
spectrum ranges from relatively mild phenotypes, which gen-
erally cause few problems besides local discomfort and visible
disfigurement, to subtypes with severe complications such as
joint contractures and limb length discrepancies. Eosinophilic
fasciitis (EF,Shulmansyndrome) is often regardedasbelonging
to the severe end of the morphea spectrum. The exact driving
mechanisms behindmorphea andEF pathogenesis remain to be
elucidated. However, extensive extracellular matrix formation
and autoimmune dysfunction are thought to be key pathogenic
processes. Likewise, these processes are considered essential in
systemic sclerosis (SSc) pathogenesis. In addition, similarities
in clinical presentation between morphea and SSc have led to
many theories about their relatedness. Importantly, morphea
may be differentiated from SSc based on absence of sclero-
dactyly, Raynaud’s phenomenon, and nailfold capillary chan-
ges. The diagnosis of morphea is often based on characteristic
clinical findings. Histopathological evaluation of skin biopsies
and laboratory tests arenot necessary in themajorityofmorphea
cases. However, full-thickness skin biopsies, containing fascia
and muscle tissue, are required for the diagnosis of EF.
Monitoring of disease activity and damage, especially of sub-
cutaneous involvement, is one of the most challenging aspects
of morphea care. Therefore, data harmonization is crucial for
optimizing standard care and for comparability of study results.
Recently, the localized scleroderma cutaneous assessment tool
(LoSCAT) has been developed and validated for morphea. The
LoSCAT is currently the most widely reported outcome mea-
sure for morphea. Care providers should take disease subtype,
degree of activity, depth of involvement, and quality-of-life
impairments into account when initiating treatment. In most
patientswith circumscribed superficial subtypes, treatmentwith
topical therapies suffices. In more widespread disease, UVA1
phototherapy or systemic treatment with methotrexate (MTX),
with or without a systemic corticosteroid combination, should
be initiated. Disappointingly, few alternatives for MTX have
been described and additional research is still needed to opti-
mize treatment for these debilitating conditions. In this review,
we present a state-of-the-art flow chart that guides care provi-
ders in the treatment of morphea and EF.
Key Points
Progress has been made in elucidating the
immunological pathways involved in morphea.
Disease monitoring by reliable and sensitive
outcome measures is improved by the localized
scleroderma cutaneous assessment tool (LoSCAT);
however, especially for deep involvement, additional
validated outcome measures are required.
This reviewprovides two state-of-the-art algorithms that
guide care providers with regard to (i) diagnostic work-
up and diseasemonitoring, and (ii) treatment ofmorphea
and eosinophilic fasciitis.
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1 Introduction
Morphea, also known as localized scleroderma, encom-
passes a group of idiopathic sclerotic skin diseases. Con-
troversy exists with regard to nomenclature of the disease
spectrum. In some countries, localized scleroderma is the
preferred overarching term, because morphea is regarded
as one of the subtypes of the wider disease spectrum.
However, morphea is the preferred term in the United
States (US), because localized scleroderma could lead to
unwanted confusion with the term systemic sclerosis, a
systemic disorder with a different plethora of clinical and
pathological signs and symptoms [1]. For the purpose of
this review, we will use the term morphea.
The spectrum of morphea consists of heterogeneous
disease phenotypes. Solitary sclerotic lesions, which gen-
erally cause few problems besides local discomfort and
visible disfigurement, reflect the mild side of the spectrum
[2, 3]. Conversely, sclerosis can cause severe complica-
tions in the linear subtype; limb length discrepancies and
joint contractures may occur [1, 4, 5].
This review encompasses a description of the clinical
aspects of the morphea subtypes. Eosinophilic fasciitis (EF,
also known as Shulman Syndrome), often regarded as part of
the morphea spectrum, is included in this review. Addi-
tionally, we describe recent developments in understanding
of disease pathogenesis and potential outcome measures.
Lastly, we present two state-of-the-art flow charts, which
guide care providers with regard to (i) diagnostic work-up
and diseasemonitoring and (ii) treatment ofmorphea andEF.
2 Epidemiology, Classification and Presentation
2.1 Epidemiology
The rarity of morphea is reflected in the annual incidence
rates which are reported to be between 3.4 and 27 cases per
1,000,000 [6–8]. Females are more frequently affected than
males (ratio: 2.4–5.0 to 1) [1, 9–11]. The peak incidence is
bimodal with peaks between 7 and 11 years for pediatric-
onset disease [1, 10–13] and 44–47 years for adult-onset
disease [10, 12]. The incidence and prevalence of EF is
unknown. The disease predominantly affects patients in their
fourth and fifth decade of life [14–16]. Only a few case
reports describe childhood-onset disease [11, 14, 15, 17–21].
2.2 Classification
Multiple classification schemes have been proposed
throughout the years. However, consensus with regard to
one superior classification system is currently lacking.
Classification by Laxer and Zulian [22] describes the fol-
lowing five subtypes: (i) circumscribed morphea (including
a superficial and deep variant), (ii) linear morphea (in-
cluding a limb/trunk variant and head variant), (iii) gen-
eralized morphea, (iv) the pansclerotic subtype, and (v) the
mixed subtype (Table 1). Other classification systems
include more uncommon subtypes such as guttate and
bullous morphea [23, 24]. Secondly, these systems include
diagnoses which are debated to be part of the morphea
spectrum, such as atrophoderma of Pasini and Pierini,
extragenital lichen sclerosis et atrophicus, and EF. In the
Table 1 Classification of morphea subtypes by Laxer and Zulian [22]
Main group Subtype Description
(I) Circumscribed
morphea
Superficial Oval or round circumscribed areas of induration limited to epidermis and dermis, often with altered
pigmentation and violaceous, erythematous halo (‘lilac ring’). They can be single or multiple
Deep Oval or round circumscribed deep induration of the skin involving subcutaneous tissue extending to fascia
and may involve underlying muscle. The lesions can be single or multiple. Sometimes the primary site of
involvement is in the subcutaneous tissue without involvement of the skin
(II) Linear morphea Trunk/
limbs
Linear induration involving dermis, subcutaneous tissue, and sometimes muscle and underlying bone, and
affecting the limbs and the trunk
Head En coup de sabre (ECDS): Linear induration that affects the face and the scalp and sometimes involves
muscle and underlying bone
Parry–Romberg or progressive hemifacial atrophy: loss of tissue on one side of the face that may involve
dermis, subcutaneous tissue, muscle and bone. The skin is mobile
(III) Generalized morphea Induration of the skin starting as individual plaques (four or more and larger than 3 cm) that become
confluent and involve at least two out of seven anatomic sites (head/neck, right upper extremity, left upper
extremity, right lower extremity, left lower extremity, anterior trunk, posterior trunk)
(IV) Pansclerotic morphea Circumferential involvement of limb(s) affecting the skin, subcutaneous tissue, muscle and bone. The lesion
may also involve other areas of the body without internal organ involvement
(V) Mixed morphea Combination of two or more of the previous subtypes. The order of the concomitant subtypes, specified in
brackets, will follow their predominant representation in the individual patient [i.e., mixed morphea
(linear-circumscribed)]
492 J. S. Mertens et al.
authors’ opinion, EF belongs to the spectrum of morphea,
based on the fact that the largest case series reported
concomitant morphea in 29–40% of the patients [14–16].
2.3 Clinical Characteristics
2.3.1 General Findings
Early, progressive morphea is characterized by erythematous
or violaceous cutaneous lesions. As the disease progresses,
sclerotic plaques develop at the center of these lesions. This
leads to the appearanceof a yellow-white sclerotic plaquewith
an erythematous or violaceous border, the so-called ‘lilac
ring’ (Fig. 1). In some patients, development of hyperpig-
mentation is the predominant feature and sclerosis can be
limited or absent (Fig. 2). In the majority of patients, skin
softens in months to years. Consecutively, signs of residual
damage, such as pigment alterations and cutaneous and sub-
cutaneous atrophy, may develop. In most patients, the disease
is self-limiting within 3–5 years. However, in some patients
morphea remains progressive for multiple years or flares of
disease occur frequently [1, 10, 25].
2.3.2 Circumscribed Superficial Morphea
In circumscribed superficial morphea, also known as
‘morphea en plaque’, involvement is limited to the dermis
[9, 10, 13]. Solitary or few plaques predominantly affect
the trunk, waist and submammary region. Circumscribed
superficial morphea is the most common subtype in adults
and generally causes few problems besides local discom-
fort and visible disfigurement.
2.3.3 Circumscribed Deep Morphea
In circumscribed deep morphea (morphea profunda),
sclerosis reaching into the subcutis is present and may
extend into the fascia and muscle. Deep morphea is a rare
subtype in both the adult and pediatric populations (*5%)
[1, 9, 10]. Lower extremities are often affected symmetri-
cally, where sclerosis might cause contractures and lead to
subcutaneous atrophy.
2.3.4 Linear Morphea
In linear morphea, sclerosis may be limited to the dermis,
but deeper involvement is often present. The ‘band-like’
cutaneous sclerosis (Fig. 3) frequently causes contractures
[1, 4]. Additionally, limb-length discrepancies may occur
[1] (Fig. 4). In the majority of patients, the disease remains
unilateral. Linear morphea is the most common subtype in
childhood-onset morphea (*65%) [11], but disease onset
might occur during adulthood as well [4, 10]. Linear
morphea of the limbs and trunk is characterized by a
chronic disease course, as the disease may remain active
after many decennia [26, 27] and recurrences are reported
in a large proportion of both adults and children
[4, 10, 25, 28, 29].
Fig. 1 Circumscribed superficial morphea (morphea en plaque). A
yellow-white sclerotic plaque with an erythematous or violaceous
border, the characteristic ‘lilac ring’
Fig. 2 Generalized morphea. Example of a patient with absence of
induration, but extensive hyperpigmentation
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The ‘en coup de sabre’ (ECDS) subtype most frequently
affects the paramedian forehead. Linear lesions may extent
onto the scalp, where they cause alopecia (Fig. 5). This
subtype might be accompanied by ocular [30, 31], neuro-
logical [1, 11, 32] and odontostomatologic [33–35] com-
plications. Progressive hemifacial atrophy (Parry–Romberg
syndrome) is characterized by diffuse unilateral subcuta-
neous atrophy of the face. This subtype is often regarded
part of a spectrum with ECDS because 71% of the patients
have overlaying cutaneous sclerosis [32, 36]. However,
studies that investigate the connection between these two
conditions are lacking.
2.3.5 Generalized Morphea
Generalized morphea is characterized by large superficial
coalesced plaques on multiple body sites (Fig. 6). Gener-
alized morphea is more frequently present in adults than
children [9, 10, 13]. Sclerosis is usually present on the
trunk, arms, and legs with sparing of the face, hands, and
feet.
2.3.6 Eosinophilic Fasciitis (EF)
The onset of EF is characterized by acute or subacute
development of pitting edema and erythema. As the disease
progresses, edema is gradually replaced by a ‘peau d’or-
ange’ aspect as deep sclerosis starts to develop (Fig. 7).
Extremities are affected symmetrically, with exclusion of
Fig. 3 Linear morphea of the upper extremity
Fig. 4 Linear morphea of the lower extremity. Limb length discrep-
ancy and subcutaneous atrophy in burned-out disease (left leg)
Fig. 5 Linear morphea on the paramedian forehead (en coup de
sabre) crossing onto the scalp causing alopecia
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hands and feet. Neck and truncal involvement is reported in
widespread disease. Cutaneous involvement may be
accompanied by general symptoms such as weight loss,
myalgia and asthenia [14, 15, 21].
3 Histopathology
3.1 Skin Biopsy in Morphea
Histopathological characteristics correlate with the clinical
state of morphea. Evaluation of early active morphea,
represented by a biopsy of the inflammatory border, reveals
a perivascular infiltrate composed of lymphocytes and
plasma cells, possibly accompanied by eosinophils and
macrophages. Evaluation of sclerotic skin demonstrates
thickened and homogenized collagen bundles at the pap-
illary and reticular dermis. The abundant collagen bundles
enclose eccrine glands and few dermal blood vessels with
fibrotic walls and narrow lumina may be observed as the
sclerosis progresses. Subcutaneous infiltration and sclerosis
reflect deeper involvement.
We recommend a diagnostic skin biopsy only in case of
an unclear clinical presentation of morphea. The clinical
appearance of the biopsy site (inflammatory border versus
sclerotic center) should be mentioned to the pathologists
for optimal clinicopathological correlation.
3.2 Full-Thickness Biopsy in EF
A full-thickness biopsy, containing fascia and muscle, is
the golden standard for the diagnosis of EF. Histology
typically displays a thickened fascia infiltrated by lym-
phocytes accompanied by eosinophils, plasma cells, and
macrophages [14, 15]. The presence of eosinophils is
transient and may be absent if patients have prolonged
disease or receive systemic corticosteroids (SCSs) or
immunosuppressive drugs (ISDs). Adjacent myositis is
frequently observed [37]. The presence of thickened der-
mal collagen fibers may reflect the presence of concomitant
superficial morphea [14, 15]. More recently, magnetic
resonance imaging (MRI) [38–40], ultrasound [41, 42], and
positron emission tomography (PET) [43–45] have been
reported to be helpful in establishing the diagnosis by
decreasing the likelihood of sampling errors for deep
biopsies or by visualizing the fasciitis.
4 Pathogenesis
4.1 Pathological Hallmarks of Morphea
The exact driving mechanisms behind morphea pathogen-
esis remain to be elucidated. However, extensive extra-
cellular matrix (collagen) formation and autoimmune
dysfunction are thought to be key pathogenic processes
[46–48]. Likewise, these processes are considered essential
in systemic sclerosis (SSc) pathogenesis. The similarities
Fig. 6 Severe case of generalized morphea on the trunk with atrophy
of both breasts
Fig. 7 Peau d’orange aspect on upper extremity in a patient with
eosinophilic fasciitis
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between the two diseases have led to many theories about
their relatedness. Based on this possible connection, most
theories for morphea pathogenesis are deduced from SSc.
Endothelial dysfunction, immune dysregulation, and
excessive collagen deposition are regarded as key hall-
marks for SSc pathogenesis [49, 50]. In recent years,
research in SSc has led to some insight into these hallmarks
and their inter-relationship. The evidence and relevance for
these hallmarks in morphea pathogenesis are described in
the following sections.
4.1.1 Vascular Dysfunction
For SSc, endothelial dysfunction is clinically reflected in
the presence of Raynaud’s phenomenon and visible chan-
ges on capillaroscopy (nailfold lesions) [51]. No such
clinicopathological correlation exists for morphea. How-
ever, the propensity of pericyte hyperplasia in capillar and
venular walls and increased capillary density in active
morphea lesions have been reported [52].
4.1.2 Immune Dysregulation
4.1.2.1 Autoimmunity Autoimmunity is likely involved
in the pathogenesis because of the presence of autoanti-
bodies in a proportion of the morphea patients
[9, 11, 53–58]. Secondly, the presence of concomitant
autoimmune diseases in morphea patients and their rela-
tives supports involvement of autoimmunity [5, 11, 13, 59].
Recently, a study including 211 morphea patients and 726
matched controls investigated HLA class I and II typing.
The strongest associations with morphea were found with
the HLA Class II allele DRB1*04:04 and class I allele
HLA–B*37. Comparison of the risk alleles for the morphea
cohort versus other autoimmune diseases revealed only one
allele in common between morphea and SSc. However,
many more alleles showed similarity with other autoim-
mune diseases such as rheumatoid arthritis [60].
4.1.2.2 Cytokines and Chemokines Increased serum
levels of the adhesion molecules Vascular Cell Adhesion
Molecule-1 (VCAM-1), Intracellular Cell Adhesion
Molecule-1 (ICAM-1) and E-Selectin have been reported
in morphea patients [61, 62]. These molecules might be
involved in early recruitment of inflammatory cells such as
T cells, monocytes, and other immune cells.
Initial studies demonstrated elevation of classic profi-
brotic T helper cell 2 (Th2) cytokines IL-4 and IL-13 (and
IL-2, 6, and 8) in serum of 48 morphea patients. Likewise,
IL-4 and IL-13 elevation has been demonstrated in circu-
lation, skin, and lung tissue of SSc patients [63–65].
Recently, a cross-sectional study performed a 29-plex
Luminex, which included Th1, Th2 and Th17 cytokines and
chemokines on plasma of 69 pediatric morphea patients
and 71 controls. Elevation of interferon-c (IFN-c)-induced
protein 10 (IP-10, CXCL10), IL-12p70 and IFN-c sug-
gested a proinflammatory Th1 predominance, whereas IL-
17a elevation signified a proinflammatory Th17 predomi-
nance. Elevation of these proinflammatory Th1 and Th17
cytokines and chemokines correlated with shorter disease
duration. In contrast to the Th1/17 predominance, Th2
cytokines IL-4, IL-5, and IL-13 were not significantly
elevated [66]. IL-17a gene upregulation has also been
reported in peripheral blood mononuclear and skin samples
from morphea patients. This study confirmed the correla-
tion between IL-17a elevation and shorter disease duration
[67]. Tumor necrosis factor-a (TNF-a), an effector cyto-
kine affiliated with the Th1 and Th17 lineage was shown to
be increased in active disease versus inactive disease [66].
The association of TNF-a levels and disease activity was
also shown in a previous study [68].
In conclusion, it is unclear whether a Th1/17 or Th2
predominance is present in morphea. One postulated theory
is Th1 and Th17 predominance in early, active disease and
Th2 predominance in the fibrotic phase of the disease.
4.1.3 Excessive Extracellular Matrix Formation
Development of cutaneous or subcutaneous fibrosis is the
key characteristic of morphea. Fibrosis is a result of
excessive collagen synthesis and decreased degradation.
Transforming growth factor-b1 (TGF-b1) has been shown
to increase the expression of several collagen types and
other extracellular matrix components in morphea and SSc
[69–71]. Additionally, TGF-b1 has inhibitory effects on
matrix degradation. Therefore, TGF-b is regarded a key
player in morphea and SSc pathogenesis. However, the
processes leading to excessive TGF-b synthesis in morphea
remain poorly understood. Recent reports in SSc showed
TGF-b-dependent fibrosis development via toll-like
receptor (TLR) signaling [72–75]. Most interestingly, some
of these reports demonstrated endogenous ligands (mito-
chondrial DNA [72], fibronectin EDA (extra domain-A)
[73] and tenascin-C [75]) for these TLRs. These findings
integrate innate immunity and fibrosis development. The
role of the innate immune system, via TLR signaling, in
fibrogenesis remains to be investigated in morphea. How-
ever, a previous report of tenascin upregulation in morphea
skin samples might hint towards involvement of the innate
immune system in morphea pathogenesis [76].
4.2 Epigenetics
Low concordance rates of autoimmune diseases in
monozygotic twins suggest additional pathogenic mecha-
nisms besides genetic factors [77]. The field of epigenetics
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investigates heritable changes that influence gene expres-
sion without altering the DNA sequence; these changes
include DNA methylation, post-translational modification
of histones and microRNAs (miRNAs) [78]. MiRNAs are
short non-coding RNAs of 18–23 nucleotides that bind
messenger RNAs (mRNAs) and thereby inhibit their
translation or induce mRNA degradation. A study in 2013
was the first to report miRNA dysregulation in morphea.
This study reported let-7a downregulation in morphea skin
and circulation. Additionally, experimental let-7a overex-
pression, or inhibition, affected protein expression of type I
collagen [79]. A second study reported miRNA-196a
downregulation in serum and involved skin of morphea
patients. Transfection of an miRNA-196a inhibitor into
normal cultured fibroblasts upregulated type 1 collagen
protein in vitro [80]. Lastly, a recent study reported
upregulation of miRNA-155 in SSc and morphea skin.
Most interestingly, this study showed the potential of
miRNA as a therapeutic target by decreasing the dermal
thickness, collagen deposition, and number of activated
fibroblasts upon topical administration of a miRNA-155
blocking agent in a murine bleomycine-induced fibrosis
model [81]. The potential of miRNA as a therapeutic
option in humans is currently being investigated in a phase
I trial with MRG-201, a molecule which mimics miRNA-
29 activity (clinicaltrials.gov NCT02603224).
4.3 Environmental Factors
Multiple environmental factors have been proposed to be
involved in morphea development. The role of friction,
long-term pressure, or mechanical factors such as vacci-
nation or other injections is repeatedly reported in 13–16%
of morphea patients [1, 11, 82]. Secondly, morphea is an
uncommon complication after radiation therapy. A recent
literature review summarized 66 cases with radiation-in-
duced morphea (RIM) [83]. Radiation may lead to secre-
tion of Th2 cytokines (Il-4 and -5), which leads to TGF-b-
mediated fibrogenesis.
For multiple decades, studies have reported inconsistent
results with regard to the association of Borrelia burgdorferi
(B. Burgdorferi) and morphea. Results vary from detection
of B. burgdorferi in case reports and large proportions of
patients in case series [84–87], to complete absence of
detectable B. burgdorferi in other studies [88–97]. The dif-
ferent techniques being reported, in combination with dif-
ferent borrelia strains present in different geographical
locations, makes it difficult to come to a conclusion for a
large group of morphea patients. In the authors’ opinion, it is
unlikely that B. burgdorferi is involved in morphea patho-
genesis for a large proportion of patients.
Interestingly, recent case reports almost exclusively
report TNF-a inhibitors in drug-induced morphea [98–101].
Conversely, two cases have described beneficial effects of
infliximab in severe morphea cases [102, 103]. Moreover,
elevation of TNF-a in circulation in active morphea endor-
ses the role of this cytokine in the development of morphea
[66, 68]. However, the exact role of TNF-a still remains to
be elucidated. In addition to TNF-a inhibitors, multiple
other drugs and injections have been implicated in cases of
drug-induced morphea. A review including 15 cases of drug-
induced morphea concluded that drug-induced morphea was
extremely rare, drug withdrawal did not lead to remission in
most patients, and some of the drugs could be directly linked
to connective tissue metabolism [104].
4.4 Pathogenesis of EF
The pathogenesis of EF remains unknown. Numerous asso-
ciations with potential etiological factors have been proposed
in case reports. Most of these factors have also been reported
in association with morphea (i.e., B. burgdorferi infection
[105], radiation therapy [106], and insect bites [107]). The
most commonly reported etiological factor for EF is strenuous
exercise or trauma preceding disease onset. Two case series,
consisting of 52 [15] and 63 patients [16], reported exercise to
be suggestive for disease induction in 46 and 28% of the
patients, respectively. However, the mechanisms leading to
clinical phenotype remain unknown.
5 Laboratory Testing
5.1 Autoantibodies
To date, no morphea-specific autoantibodies have been dis-
covered. This is in contrast to SSc, for whichmultiple specific
autoantibodies (anticentromere, anti-topoisomerase 1 and
anti-RNA polyisomerase III antibodies) have been reported
and are routinely being screened in standard care [108].
Antinuclear antibodies (ANAs) have been reported in
5.9–68% of morphea patients [9, 11, 13, 54–56, 58]. Pre-
vious retrospective studies reported increased ANA fre-
quencies in severe subtypes such as linear and generalized
morphea [13, 54]. Recently, a prospective study with 187
morphea patients could not confirm differences in ANA
prevalence between the different subtypes. This study
reported ANAs to be present in 34% of the complete group,
with ANA prevalences only varying between 33 and 36%
in the different disease subtypes [53]. Additionally, this
study showed single-stranded DNA antibodies (ssDNA
abs) only to be present in 8% of the complete group and
13% in the linear subtype, versus 7% in controls. Retro-
spective studies reported ssDNA abs in 29–39% of the
linear subtype [54, 55]. Antihistone antibodies (AHAs) are
consistently reported to be increased in the linear subtype
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(18–42%) [53, 54, 56], whereas conflicting results exist
with regard to AHA and the generalized subtype [53, 56].
Lastly, antibodies to cardiolipin [11, 109–111], phospho-
lipid [110], U1 ribonucleoproteins [112], U3 ribonucleo-
proteins [113], MMP-1 [114], and antinucleosome [58]
have been described in morphea.
For morphea, autoantibodies remain of limited clinical
use; no specific autoantibodies have been identified and no
associations have been reported between any of the pre-
viously reported antibodies or titers and clinical activity or
severity measures in the complete group of morphea
subtypes.
In conclusion, we do not recommend testing of
autoantibodies for diagnostic and disease monitoring
purposes.
5.2 Borrelia burgdorferi
Section 4.3 encompasses a more detailed description of the
role of borrelia in morphea development. Based on evi-
dence, serological testing may be considered in atypical
presentation of morphea.
5.3 Other Laboratory Tests
Inflammatory serological markers are upregulated in a
minority of morphea patients and do not correlate with
disease activity [11]. Therefore, we do not recommend
routine testing of inflammatory serological markers.
5.4 Laboratory Tests for EF
Peripheral eosinophilia and elevation of inflammatory mark-
ers may be present in the early stages of EF. However, these
findings are transient and may be absent in later stages of the
disease or when patients receive SCS or ISD treatment. We
recommend routine testing of absolute eosinophil counts and
inflammatorymarkers in the initial phase of thedisease and for
the detection of disease reactivation [14, 15]. Autoantibodies
may be detected in 15–20% of patients, whereas specific
antibodies are absent in themajority of patients.Autoantibody
testingmaybeuseful in the differentiation versusSSc [14, 15].
In addition, anti-neutrophil cytoplasmic antibody (ANCA)
testing can be performed in cases where eosinophilic granu-
lomatosis with polyangiitis (EGPA) is considered as part of
the differential diagnosis [115].
6 Outcome Measures
Validated outcome measures for disease activity and
damage are essential for optimal standard of care. Sec-
ondly, data harmonization is crucial for comparability of
study results. Recently, a comprehensive systematic review
described tools for determining disease activity in morphea
[116]. In the following sections, we describe the most
promising outcome measures.
6.1 Clinical Scores
The localized scleroderma cutaneous assessment tool
(LoSCAT) is a composite of the modified localized scle-
roderma severity index (mLoSSI) [117] and localized
scleroderma skin damage index (LoSDI) [118]. The
mLoSSI assesses signs of disease activity (expansion of
disease, presence of erythema, and skin induration). The
LoSDI scores cutaneous and subcutaneous atrophy, and
pigment alterations; signs which reflect disease damage. In
addition to the LoSCAT, physician global assessment of
disease activity (PhysGA-A) and damage (PhysGA-D)
have also been investigated in the development of the
LoSCAT score [117, 118]. The Dyspigmentation, Indura-
tion, Erythema and Telangiectasia (DIET) score poorly
discriminates between disease activity and disease damage;
similar scores can reflect either active or inactive disease
[119, 120]. Lastly, several one- or two-dimensional clinical
scores, such as the modified Rodnan skin score [121–123]
(mRSS), the modified skin score (mSS, by Zachariae)
[124, 125] and the computerized skin score (CSS) [126]
have been described. These scores share the downside of
only capturing skin sclerosis as a sign of disease activity.
Therefore, based on current literature, LoSCAT in combi-
nation with PhysGA-A and PhysGA-D are the recom-
mended clinical outcome measures for superficial morphea
assessment.
6.2 Miscellaneous Outcome Measures
Ultrasound is widely reported for the assessment of mor-
phea activity [116]. However, the downside of ultrasound
is the wide variability in equipment reported between
studies. The Localized Scleroderma Clinical and Ultra-
sound Study Group (LOCUS) has developed a standardized
ultrasound imaging protocol, which should lead to data
harmonization [127]. Another technique commonly repor-
ted is infrared thermography (IRT). Multiple studies have
demonstrated correlations between lesion temperature and
clinical activity status of the morphea lesions [116]. Lastly,
durometry is a tool used to measure material hardness.
Originally, durometry was described as a reliable method
for the assessment of morphea skin hardness [124].
Recently, a study with 23 pediatric patients demonstrated
that durometry was able to discriminate between affected
and unaffected skin and that it was sensitive to detect
change in lesions [128]. The usefulness of durometry
remains limited as lesions located at bony surfaces, such as
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scalp, and skin lesions are not suited to assessment with
durometry [129, 130].
In conclusion, in superficial morphea, high frequency
ultrasound and IRT are the most promising techniques for
monitoring disease activity, in addition to the LoSCAT.
6.3 Outcome Measures for EF
To our knowledge, no outcome measures have been vali-
dated for EF. Therefore, we recommend the use of outcome
measures known from SSc and morphea research. We
recommend LoSCAT in combination with PhysGA-A and
PhysGA-D, possibly accompanied by ultrasound and IRT,
for the assessment of superficial involvement. Lastly,
movement restrictions may be assessed by passive range of
motion measurements.
7 Assessment of Musculoskeletal Involvement
Slow progression of musculoskeletal involvement may be
notoriously difficult to measure between consecutive visits,
but accumulated damage may be significant over a longer
period of time. This emphasizes the necessity of additional
imaging tools or biomarkers which reflect active deep
disease.
7.1 Recommendations for Morphea
A retrospective study reported MRI findings in 43 morphea
patients; MRI enabled confirmation of musculoskeletal
abnormalities in all but one of the patients in whom mus-
culoskeletal involvement was clinically suspected [131]. A
recent retrospective study confirmed the potential of MRI
in detection of musculoskeletal involvement [132]. More
importantly, a longitudinal study reported MRI findings to
be sensitive to changes in patients with deep morphea who
were being treated with ISDs [133].
One study reported the additional value of electromyog-
raphy (EMG) in detection of muscle dysfunction in patients
with linear morphea [134]. Lastly, ultrasound has been
reported in the monitoring of muscle involvement in deep
morphea. However, the usefulness of this technique is highly
operator-dependent [135]. In conclusion, the exact role of
EMGand ultrasound requires further investigation. Based on
the current evidence, we recommend MRI for monitoring of
musculoskeletal involvement in morphea when indicated.
However, we do not recommend routine MRI assessment.
7.2 Recommendations for EF
A retrospective study described serial MRI findings in six
EF patients. Pretreatment MRI evaluation showed strong
fascial enhancement, especially after intravenous (IV)
administration of an extracellular gadolinium-based con-
trast agent. Post-therapy MRI evaluation during follow-up
showed complete resolution of the characteristic MRI
changes of the superficial and deep muscle fasciae in those
patients who had complete clinical remission (n = 5) [40].
Another case series described MRI findings in six EF
patients. Pretreatment MRI findings (n = 6) showed fascial
thickening and hyperintense signal within the fascia in
fluid-sensitive sequences. The post-therapy images (n = 3)
showed marked improvement in two and mild but definite
improvement in the other [136]. Case reports confirm the
added value of MRI for both diagnostic purposes [137] and
for the assessment of the fasciitis [39, 138]. In addition,
ultrasound [41, 42] and positron emission tomography
(PET) [43–45] have also been reported to be helpful for
similar purposes. In conclusion, MRI may be considered
for the assessment of EF.
8 Differential Diagnosis
8.1 Differentiation Diagnosis of Morphea
Evaluation of the differential diagnosis for the complete
morphea spectrum is beyond the scope of this review and is
described elsewhere [24]. Differentiation between morphea
and SSc is commonly requested in an outpatient clinic. In
the vast majority of patients, differentiation between the
two diseases should be based on clinical findings and no
additional testing is necessary in the absence of SSc
suspicion.
Raynaud’s phenomenon or gastrointestinal problems are
early signs of SSc and should therefore be checked in the
patients’ history. Signs of SSc such as sclerodactyly, digital
ulcers, pitting scars, puffy fingers, calcinosis cutis,
telangiectasia, and diffuse facial sclerosis are rarely present
in morphea and should be excluded by clinical
examination.
Two studies investigated differentiating characteristics
between morphea and SSc skin biopsies. These studies
identified abundant cellular infiltrates in morphea com-
pared with SSc, even in the sclerotic phase of morphea.
However, most signs overlapped and differentiation
remained difficult [139, 140]. Therefore, we do not rec-
ommend routine skin biopsies for the purpose of differ-
entiation between morphea and SSc.
If SSc suspicion is present at any of the aforementioned
steps, complete screening for SSc, including extensive
laboratory testing, pulmonary imaging and functional
testing, cardiac imaging, and nailfold capillaroscopy, is
recommended [108].
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8.2 Differential Diagnosis of EF
The initial presentation of EF is characterized by an acute
or subacute onset of pitting edema, erythema, myalgia, and
arthralgia, accompanied by elevated inflammatory markers
[erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP)] and peripheral eosinophilia. After this initial
inflammatory phase, sclerosis gradually starts to develop at
affected body sites [15, 21]. The differential diagnosis of
EF consists of morphea, SSc, scleroderma-like conditions,
and miscellaneous diseases characterized by signs of
inflammation and peripheral eosinophilia.
Differentiation between morphea and EF is mainly
based on the characteristic distribution of cutaneous scle-
rosis in different morphea subtypes (i.e., linear morphea)
[48]. In addition, histological demonstration of a fasciitis
accompanied by eosinophils in the infiltrate support the
diagnosis of EF [15]. However, histological differentiation
with deep morphea, especially in the presence of wide-
spread sclerosis, may be challenging. In such cases, clinical
findings such as symmetrical distribution, a pronounced
inflammatory phase, and detection of peripheral eosino-
philia point towards EF.
Eosinophilic fasciitis and SSc are both characterized by
initial inflammation, followed by cutaneous fibrosis. Facial
and acral involvement are uncommon in EF and point toward
SSc. In addition, presence of Raynaud’s phenomenon,
abnormal nailfold capillaroscopy, specific autoantibodies,
and internal organ involvement are absent in EF and fre-
quently found in SSc. Lastly, histopathological demonstra-
tion of a fasciitis supports the diagnosis of EF [108].
Eosinophilia-myalgia syndrome (EMS) [141], caused by
L-tryprophane ingestion, and toxic oil syndrome [142], are
two examples of scleroderma-like syndromes which may
be difficult to differentiate from EF, even by full-thickness
biopsies. However, internal organ involvement differenti-
ates the conditions from EF. Likewise, hypereosinophilic
syndrome (HES) [143] and EGPA [144] are also charac-
terized by organ involvement. In addition, the absence of
cutaneous sclerosis in both HES and EGPA should aid
differentiation with EF.
Lastly, nephrogenic systemic fibrosis should be suspected
in patients with advanced renal failure, or a history of
gadolinium administration. In addition to the patients’ his-
tory, involvement of the acra and absence of eosinophilia
supports the diagnosis of nephrogenic systemic fibrosis.
9 Referral and Flow Chart
Figure 8 displays a flowchart which guides the care pro-
vider with regard to diagnoses and complication
management.
9.1 Morphea ECDS and Progressive Facial
Hemiatrophy (Parry–Romberg Syndrome)
Referral to an ophthalmologist should be considered to
detect complications such as eyelid abnormalities, anterior
uveitis, and episcleritis [30]. Odontostomatologic compli-
cations should be managed accordingly in cooperation with
an oral maxillofacial surgeon and/or dentist [33–35].
Lastly, neurological manifestations consisting of seizures
and headaches [145] may occur and referral to a neurolo-
gist could be considered to rule out central nervous system
involvement [32, 146–150].
9.2 Eosinophilic Fasciitis
Eosinophilic fasciitis manifests secondary to malignancy in
a minority of patients (5–10%). Association with hemato-
logical malignancy is more common than association with
solid neoplasms [14, 15, 151]. Various screening modali-
ties, such as laboratory testing, X-ray, CT or PET scan,
ultrasound and endoscopy, may be employed, dependent on
the patient risk profile and additional signs of malignancy.
9.3 Musculoskeletal Complications
Musculoskeletal complications (arthralgia, contractures,
and arthritis) are reported in up to 40% of morphea and EF
patients [1, 5, 15]. We recommend consultation of a
rheumatologist in the presence of musculoskeletal
complications.
10 Treatment
Care providers should take disease subtype, degree of
activity, depth of involvement, and quality-of-life impair-
ments into account when initiating treatment. In most
patients with circumscribed superficial subtypes, treatment
with topical therapies suffices. In widespread superficial
disease, phototherapy or systemic treatment with
methotrexate (MTX) should be initiated. For deep involve-
ment,MTX is considered first-line treatment. The addition of
SCS should be considered in case of severe disease, rapid
progression, or (looming) contractures. Figure 9 shows an
algorithmwhich guides care providers in treatment decisions
for the different subtypes, including EF.
10.1 Topical Therapy
10.1.1 Topical and Intralesional Corticosteroids
Topical corticosteroids (TCSs) are first-line therapy for
superficial morphea. However, no studies have reported
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efficacy of TCSs in morphea. Based on expert opinion, we
regard TCS first-line treatment for superficial circum-
scribed morphea. We recommend a highly potent TCS
once a day for up to 4 weeks or a moderately potent TCS
once a day for up to 3 months. Additionally, long-term
TCS therapy should be in the form of interval therapy [24].
As with TCS, there are no studies reported for intralesional
corticosteroids.
10.1.2 Topical Tacrolimus 0.1% Ointment
A double-blind, randomized controlled trial (RCT) with
tacrolimus 0.1% ointment reported significant improve-
ment in durometry and clinical scores [152]. A 3-month
open-label study with topical tacrolimus 0.1% ointment
twice daily under occlusion demonstrated complete reso-
lution of early lesions and softening of late sclerotic lesions
[153]. Another open-label study reported improvement in 9
out of 13 patients with topical tacrolimus 0.1% ointment,
twice daily without occlusion [154]. We recommend
topical tacrolimus 0.1% ointment, either with or without
occlusion, twice daily as an alternative or additional topical
therapy for superficial morphea. Additionally, based on a
recent case report, we do not recommend topical tacroli-
mus in radiation-induced morphea [155].
10.1.3 Topical Calcipotriol 0.005% Ointment
Two uncontrolled studies investigated topical calcipotriene
0.005% ointment, either with [156] or without occlusion
[157]. These studies included 31 patients and both studies
reported beneficial effects in all patients. Lastly, an
uncontrolled study with six patients reported efficacy of
combination therapy with betamethasone dipropionate and
calcipotriol 0.005% [158]. Based on the literature, we
recommend topical calcipotriol 0.005% ointment, once or
twice daily, with or without occlusion as an alternative
topical therapy for superficial morphea. Additionally,
topical calcipotriol 0.005% ointment may be prescribed
combined with TCS therapy.
Fig. 8 Flow chart for considerations with regard to diagnosis and monitoring of morphea and eosinophilic fasciitis. EF eosinophilic fasciitis,
EMG electromyography, MRI magnetic resonance imaging, SSc systemic sclerosis, US ultrasonography
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10.1.4 Miscellaneous Topical Therapies
A proof-of-concept study with topical imiquimod 5%
cream reported effectiveness, measured by decrease of
DIET and visual analog scale (VAS) scores in nine pedi-
atric patients [159]. A second prospective vehicle-con-
trolled study with 25 adult patients confirmed these results.
Imiquimod 5% cream was superior to vehicle in reducing
DIET scores at months 3, 6, 9, and 12 [120]. Both
prospective studies reported no study withdrawals and
adverse effects were minimal. Lastly, several case reports
and series confirm the beneficial effects of imiquimod 5%
[119, 160, 161]. Despite these positive study results, Ger-
man guidelines do not recommend the use of imiquimod
5% cream, based on the authors’ experience [24].
Interestingly, an open phase II trial with 12 morphea
patients reported significant reduction of mLoSSI and
durometer scores at month 6 compared with baseline with
8% pirfenidone gel, three times daily. Pirfenidone gel was
well tolerated and no side effects were reported [162].
10.2 Phototherapy
Several phototherapy modalities [ultraviolet (UV) B, pso-
ralen plus broadband UVA (PUVA), broadband UVA and
UVA1] have been investigated for morphea. Lower wave
length phototherapy (UVA) has greater potency of tissue
penetration than UVB and therefore has been studied more
extensively.
10.2.1 UVA1
The treatment potential of UVA1 (wavelength of
340–400 mm) is superior to broadband UVA
(320–400 mm), because of the lower risk for sunburn. This
allows for higher dosage delivery with fewer side effects.
Fig. 9 Flow chart for the management of morphea and eosinophilic
fasciitis. * Topical Corticosteroids (TCS): moderately potent TCS
once daily for 3 months. Highly potent TCS once daily for 1 month.
** Topical calcipotriol 0.005% ointment: once or twice daily, with or
without occlusion. Possibly in combination with TCS. *** Topical
tacrolimus 0.1% ointment: once or twice daily, with or without
occlusion. Possibly in combination with TCS.  Phototherapy:
preferably UVA1; suggested dose: 60 J/cm2 to a cumulative dose of
1460 J/cm2. If UVA1 is unavailable or impractical, alternative
modalities are broadband UVA, PUVA or UVB. Methotrexate
(MTX): adult starting dose 15 mg/week, max dose 25 mg/week;
pediatric starting dose 15 mg/m2, max dose 25 mg. Folic acid
supplementation: 0.4–1 mg/day or 5–10 mg/week. Systemic
corticosteroids (SCS): adult starting dose 0.5–1 mg/kg/day (max
60 mg) during a max of 3 months followed by tapering; pediatric
dose: 1–2 mg/kg/day, max dose 60mg/day, followed by tapering.
Intravenous methylprednisolone (IVMP): adult dose 1000 mg/day for
3 days/month for 3–6 months, possibly followed by oral SCS.
Pediatric dose 30 mg/kg/day for 3 days/month for 3 months, possibly
followed by oral SCS. a Mycophenolate Mofetil (MMF, alternative to
MTX): adult dose 1000 mg twice daily. Pediatric dose 600–1200 mg/
m2/day twice daily. A Deep/linear subtypes: treatment with MTX
monotherapy. Addition of SCS or IVMP in case of rapidly
progressive disease or in the presence of (looming) contractures. B
Eosinophilic Fasciitis: standard induction treatment with oral SCS
or IVMP in combination with MTX . PUVA psoralen plus
broadband UVA, UV ultraviolet
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Three different UVA1 dose regimens exist and have been
investigated for morphea: low dose (LD, 10–20 J/cm2)
[163–168], medium dose (MD, 30–50 J/cm2)
[121, 122, 167–170], and high dose (HD, 60–130 J/cm2)
[164]. One study demonstrated superior results for HD
compared with LD-UVA1 [164]. Additionally, one ran-
domized prospective study compared LD-UVA1, MD-
UVA1, and UVB. This study showed superior efficacy of
MD-UVA1 versus UVB but not versus LD-UVA1 [167].
Noteworthy, the first true randomized, blinded, and pla-
cebo-controlled trial with UVA1 is currently including
patients (clinicaltrials.gov NCT01799174). The maximum
dose investigated in a study consists of a cumulative dose
of 3900 J/cm2. At our center, we treat patients with 60 J/
cm2 3–5 times a week to a cumulative dose of 1460 J/cm2.
In contrast to the excellent short-term results with UVA1, a
study of 37 adults showed 2-year and 3-year recurrence
rates of 44.5 and 48.4% after UVA1 treatment, respectively
[29]. No data exists with regard to effectiveness of repeated
treatment with UVA1.
10.2.2 Miscellaneous Phototherapy Modalities
One study investigated broadband UVA (320–400 mm) in
three dose regimens (5, 10, and 20 J/cm2) for 20 sessions in
63 patients. All regimens were effective and none of them
was superior to the other regimens [171]. Two prospective
studies report beneficial effects of PUVA in 30 patients
[172, 173]. Additionally, a retrospective single-center
study confirmed these beneficial effects in 28 patients
[174]. Lastly, one prospective study demonstrated equal
effectiveness of UVB and low-dose UVA1 [167].
10.2.3 Summary and Recommendations
Based on the literature, we recommend UVA1 as first-
choice phototherapy modality for adult patients. Although
supported by less evidence, UVA1 phototherapy may also
be used in a pediatric morphea. Despite the deeper pene-
tration potential of UVA1, phototherapy should primarily
be used for superficial subtypes of morphea. Additionally,
it may be used as add-on therapy to systemic treatment in
patients with both superficial and deep manifestations.
10.3 Systemic Treatments
10.3.1 Systemic Corticosteroids (SCSs)
One open study investigated an oral SCS (prednisone,
starting dose 0.5–1 mg/kg/day followed by tapering) in 17
patients with severe morphea. Patients were treated for
5 to 70 months. This study reported a rapid response.
However, in six patients (35%), disease relapse was
observed after treatment discontinuation [175]. Addition-
ally, a retrospective study with 28 adult patients reported a
favorable response in 24 patients (86%) with an oral SCS
(prednisone, starting dose 0.3–1.0 mg/kg/day). Patients
were treated for 3–39 months. Similar to the first study,
recurrence rate was 45% after treatment discontinuation
[176]. High recurrence rates combined with an unfavorable
long-term side-effect profile leads to the recommendation
that oral SCS monotherapy is no viable long-term treat-
ment option for morphea. Intravenous methylprednisolone
(IVMP) has only been investigated in combination with
MTX and will be discussed in the following section.
10.3.2 Methotrexate
MTX, with or without the combination of IVMP and/or
oral SCS, is the most reported systemic treatment for
morphea. Best evidence results from a double-blind RCT
with 70 pediatric morphea patients, which investigated oral
MTX (15 mg/m2/week, max 20 mg) versus placebo for 12
months. Both arms received an oral SCS (prednisone,
starting dose 1 mg/kg/day, max 50 mg, followed by
tapering) for the first 3 months. Reported outcome mea-
sures consisted of a computerized skin score rate and IRT.
Improvements in outcome measures at month 12 could
only be observed in the MTX treatment arm, whereas the
placebo arm showed worsening [28].
Two prospective non-controlled studies investigated
MTX in combination with IVMP [177] or oral SCS [178]
in children. One study included ten pediatric patients who
received subcutaneous MTX 0.3–0.6 mg/kg/week (max
20 mg/week), of whom nine patients simultaneously
received IVMP (30 mg/kg for 3 days, monthly for 3
months). At the last follow-up visit, all patients who con-
tinued (n = 9) had inactive skin lesions [177]. The second
study investigated subcutaneous MTX (1 mg/kg/week,
max 25 mg) in combination with an oral SCS (prednisone
2 mg/kg/day, maximum 60 mg/day followed by tapering)
in 36 pediatric patients. All patients demonstrated signifi-
cant improvement in mLoSSI and PhysGA-A at a median
of 1.77 months [178].
Two additional prospective studies investigated adult
patients. One study investigated oral MTX (15 mg/week)
in combination with IVMP (1000 mg for 3 days, monthly)
for at least 6 months in 15 patients with severe morphea. In
the majority of patients (n = 14), a significant decrease in
mSS was observed, supported by histologic and ultrasound
assessments [179]. Another uncontrolled prospective study
investigated oral MTX (15 mg/week) monotherapy for 24
weeks in nine adult morphea patients [180]. Significant
improvements in MSS and VAS for tightness were
observed at week 24.
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In addition to prospective trials, we identified 11 retro-
spective studies which report MTX with or without IVMP
and/or oral SCS [1, 4, 25, 27, 32, 109, 181–185]. A total of
353 unique patients were identified (124 adults and 229
pediatric patients). Response rates to MTX with or without
IVMP and/or oral SCS ranged between 80–94%. In con-
trast to the high short-term response rates, (long-term)
disease recurrences are reported in 28–44% of the patients
after MTX discontinuation [1, 25, 182, 184]. A prospective
long-term follow-up study described that MTX treatment
duration was a predictor for relapse, suggesting that longer
treatment duration prevents disease relapse [186]. Lastly,
some of the retrospective studies report superior response
rates for combination therapy with MTX plus SCS com-
pared with MTX monotherapy [4, 185]. However, these
studies are prone to bias because of confounding by indi-
cation as a result of the retrospective design of these
studies.
In conclusion, MTX is an effective treatment for mor-
phea. However, no comparative studies between MTX
monotherapy and MTX plus SCS have been reported.
Therefore, no recommendations can be given as to whether
MTX should be applied with or without SCS. However,
either oral SCS or IVMP should be added to MTX in the
case of severe disease, rapidly progressive disease, or in the
presence of (looming) contractures. Recommended dosa-
ges are displayed in the legend of the flowchart (Fig. 9).
Optimal timing of systemic treatment discontinuation
remains a difficult aspect in therapeutic management.
10.3.2.1 Folic/Folinic Acid Supplementation A retro-
spective analysis of MTX treatment in 107 adult patients
showed that folic acid (5–10 mg once a week) protected
against MTX discontinuation due to adverse events [181].
Additionally, folic acid (0.4–1 mg/day) or folinic acid
(5 mg/week) is recommended by Childhood Arthritis and
Rheumatology Research Alliance (CARRA) [187].
10.3.3 Mycophenolate Mofetil (MMF)
Two studies reported MMF in severe refractory morphea.
The first study retrospectively described ten MTX- and
corticosteroid-refractory pediatric morphea patients who
were treated with MMF (600–1200 mg/m2/day). Six out of
ten patients received MMF combined with MTX treatment.
Arrest of disease progression was reported in eight patients
(80%) a reduction of erythema in seven (70%), skin soft-
ening in nine (90%), and extracutaneous manifestations in
four patients (40%). MMF was well tolerated in all patients
[188]. The second study retrospectively described MMF in
seven morphea patients (three adults and four children).
Doses ranged from 500 to 2500 mg. This study reported
disease remission in four patients (57%) and maintenance
of disease remission in one patient (14%). In the remaining
two patients (29%), MMF treatment was discontinued due
to disease progression or side effects [189]. Despite the
limited evidence for MMF in morphea, two studies showed
extensive experience with MMF in large proportions of
involved care providers [187, 190]. Based on current evi-
dence, we recommend MMF (adults 1000 mg twice daily;
children 600–1200 mg/m2/day twice daily) as an alterna-
tive to MTX.
10.3.4 Miscellaneous Systemic Treatment Options
Recent case reports describe imatinib [191–194], inflix-
imab [102, 103], rituximab [98], abatacept [195], the
mTOR inhibitors tacrolimus [196] and everolimus [197],
and mesenchymal stem-cell therapy [198] as alternative
treatment options in severe morphea. The authors recom-
mend restraint from the use of TNF-a inhibitors in the
treatment of morphea as multiple reports show morphea
can be provoked by these agents [98–101].
10.4 Recommendations for EF
Historically, HD SCS monotherapy (prednisone
0.5–2.0 mg/kg/day) was regarded as first-line treatment for
EF [14, 15, 199]. However, multiple recent retrospective
studies have shown superior response rates in patients who
are treated with a combination of HD SCS and an ISD,
especially for weekly MTX (15–25 mg/week)
[14, 16, 200]. These studies are retrospective and thus
prone to confounding by indication. Future prospective
studies should investigate the additional (long-term) effect
of MTX as was done for pediatric morphea [28].
Case series reported non- or partial responses to con-
ventional treatment in a proportion of patients [14–16].
Until recently, only case reports or small case series
described alternative treatment options [21]. However, a
recent study prospectively investigated HD pulse IV MTX
(4 mg/kg/month; median monthly MTX dose 288 mg) as
an alternative treatment option in 12 patients with EF. The
median mSS improved significantly after six pulses
(p = 0.001). Additionally, the range of motion of affected
joints and patient-reported outcomes showed significant
increases. Treatment was well tolerated and adverse events
could be managed accordingly. In this study, one patient
had to be withdrawn due to an adverse event [201].
Another recent prospective study reported superior clinical
improvement in severe EF patients treated with D-peni-
cillamine (D-pen) plus oral SCS (n = 10) versus SCS
monotherapy (n = 6). Disappointingly, four out of ten
patients in the D-pen-arm had to discontinue treatment due
to adverse events [202]. Lastly, the following alternative
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treatments have been reported in case reports and series:
infliximab [203], azathioprine [204, 205], sulfasalazine
[206], cyclosporine [207], cyclophosphamide [208], ritux-
imab [209], tocilizumab [210], sirolimus [211], PUVA
[212], IV immunoglobulins [213], and bone marrow
transplantation [214, 215].
We recommend a combination of SCS and MTX as first-
line treatment for EF. Induction therapy may consist of HD
oral SCS (prednisone 1 mg/kg/day, followed by tapering)
or IVMP (1000 mg for 3 days monthly, followed by oral
SCS) started simultaneously with weekly MTX
(15–25 mg/week) maintenance therapy.
10.5 Treatment of Disease Damage
Multiple studies report effective strategies for correction of
disease damage. However, timing of these correctional
procedures is crucial, as disease flare has frequently been
reported even after many years of disease quiescence
[10, 26]. A recent study reviews the surgical treatment
options for Parry–Romberg syndrome and ECDS and
describes the debate with regard to timing of these proce-
dures [36]. Autologous fat grafting in ECDS is reported in
multiple case reports and series [216–221]. Lastly, one case
report describes correction for limb-length discrepancy in
linear morphea of a lower extremity [222]. In the authors’
opinion, these procedures should only be performed in
long-term quiescent disease by a care provider with (ex-
tensive) experience in this field. Lastly, although evidence
is lacking, physical therapy should be considered in case of
decreased range of motion of an affected joint or when
postural deformities are present as a result of limb-length
discrepancies.
11 Conclusions
Morphea and EF pathogenesis remains to be elucidated as
well as the exact immunological relationship with SSc.
This may lead to insight into the disease mechanisms
behind these debilitating conditions and the identification
of new therapeutic targets.
Progression has been made in standardization of out-
come measures for morphea. Currently, LoSCAT is the
most promising and frequently used outcome measure.
This should lead to data harmonization and the potential to
compare future studies.
Monitoring of deep involvement of morphea is one of
the most difficult aspects of the disease. The lack of vali-
dated outcome measures for deep involvement emphasizes
the need for new biomarkers.
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